Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chloroquine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Chloroquine. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-004905-27 Sponsor Protocol Number: CBD VP 132/05 Start Date*: 2008-02-01
    Sponsor Name:Dstl
    Full Title: Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil Prophylaxis
    Medical condition: Chloroquine/proguanil is used for malaria chemoprophylaxis in areas where chloroquine-resistant Plasmodium falciparum malaria is prevalent, except in regions of Africa where chloroquine/proguanil i...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001527-14 Sponsor Protocol Number: 1 Start Date*: 2020-04-21
    Sponsor Name:Erasmus MC
    Full Title: COVID-19: addition of azithromycin to chloroquine treatment
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001010-38 Sponsor Protocol Number: Ahus-NO-COVID-19 Start Date*: 2020-03-23
    Sponsor Name:Akershus University Hospital
    Full Title: NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC...
    Medical condition: SARS-COV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037373 Pulmonary disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001441-39 Sponsor Protocol Number: VIR20001 Start Date*: 2020-05-12
    Sponsor Name:University of Oxford
    Full Title: Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
    Medical condition: COVID-19, acute respiratory illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004906-14 Sponsor Protocol Number: A0661201 Start Date*: 2015-04-07
    Sponsor Name:Pfizer Inc
    Full Title: An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro...
    Medical condition: Asymptomatic Parasitemia
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000322-21 Sponsor Protocol Number: TIP5 Start Date*: 2012-05-29
    Sponsor Name:Sanaria Inc.
    Full Title: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis
    Medical condition: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012223-29 Sponsor Protocol Number: 113165 Start Date*: 2009-09-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV ca...
    Medical condition: Immunisation against Hepatitis B and HIV in healthy adults aged between 18-52 years old, inclusive.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014772-22 Sponsor Protocol Number: version 20-07-2009 Start Date*: 2010-04-29
    Sponsor Name:MAASTRO Clinic
    Full Title: Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.
    Medical condition: To determine the toxicity of adding chloroquine in escalating doses in SCLC patients - to standard dose cisplatin-etoposide in extensive disease SCLC = STEP 1 - to standard dose concurrent radiot...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10041068 Small cell lung cancer extensive stage PT
    12.0 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-004163-21 Sponsor Protocol Number: A0661157 Start Date*: 2015-04-06
    Sponsor Name:Pfizer Inc
    Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa
    Medical condition: Malaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001373-70 Sponsor Protocol Number: ET20-076 Start Date*: 2020-04-01
    Sponsor Name:Centre Léon Bérard
    Full Title: IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizu...
    Medical condition: Patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001345-38 Sponsor Protocol Number: UNIKINON-01/HOPE Start Date*: 2020-04-02
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL
    Medical condition: Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035738 Pneumonia viral NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004952-80 Sponsor Protocol Number: A0661158 Start Date*: 2015-04-03
    Sponsor Name:Pfizer Inc
    Full Title: Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala...
    Medical condition: Intermittent Preventive Treatment In Pregnancy (IPTp)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004928-42 Sponsor Protocol Number: REM-ENY-01 Start Date*: 2020-10-12
    Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
    Full Title: Open-label study to assess the safety of REMdesivir-HU as Eligible Novel therapY for moderate and severe Covid-19 patients
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003246-93 Sponsor Protocol Number: D3461C00008 Start Date*: 2016-12-06
    Sponsor Name:Astrazeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ...
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003332-13 Sponsor Protocol Number: M13-549 Start Date*: 2016-01-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) BG (Completed) CZ (Completed) DK (Completed) BE (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) HU (Completed) GR (Completed) AT (Completed) RO (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003335-35 Sponsor Protocol Number: M13-542 Start Date*: 2016-05-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NO (Completed) SK (Completed) PT (Completed) LV (Completed) AT (Completed) FI (Completed) GR (Completed) FR (Completed) BG (Completed) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003876-38 Sponsor Protocol Number: GP13-302 Start Date*: 2015-07-21
    Sponsor Name:Hexal AG (a Sandoz company)
    Full Title: A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000610-11 Sponsor Protocol Number: NN8226-3613 Start Date*: 2013-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001697-30 Sponsor Protocol Number: COVIDNA Start Date*: 2020-04-23
    Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET
    Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA)
    Medical condition: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003011-12 Sponsor Protocol Number: RR08/8613 Start Date*: 2009-03-30
    Sponsor Name:University of Leeds
    Full Title: Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 12:16:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA